MA44934B1 - Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur - Google Patents

Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur

Info

Publication number
MA44934B1
MA44934B1 MA44934A MA44934A MA44934B1 MA 44934 B1 MA44934 B1 MA 44934B1 MA 44934 A MA44934 A MA 44934A MA 44934 A MA44934 A MA 44934A MA 44934 B1 MA44934 B1 MA 44934B1
Authority
MA
Morocco
Prior art keywords
inhibitor
raf
raf inhibitor
patient
combination therapy
Prior art date
Application number
MA44934A
Other languages
English (en)
Other versions
MA44934A1 (fr
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44934(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA44934A1 publication Critical patent/MA44934A1/fr
Publication of MA44934B1 publication Critical patent/MA44934B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La présente invention concerne une méthode consistant à neutraliser la résistance à un inhibiteur de b-raf en vue du traitement d'une maladie proliférative, ladite méthode comprenant les étapes consistant à prélever un échantillon tumoral chez le patient et à y rechercher des altérations génétiques au sein d'un ensemble de gènes comprenant braf, craf, ccnd1, cdk4, her2, igf-1r, cmet, fgfr1, fgfr2, fgfr3 egfr, map2k1, map2k2, nras, kras hras, pten, pik3ca et p16, puis à administrer au patient un traitement médicamenteux combiné comprenant l'inhibiteur de b-raf et un second inhibiteur capable de surmonter la résistance à l'inhibiteur de b-raf, ledit second inhibiteur étant choisi sur la base des altérations génétiques découvertes dans l'échantillon tumoral.
MA44934A 2013-03-21 2014-03-19 Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur MA44934B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804056P 2013-03-21 2013-03-21
PCT/IB2014/059975 WO2014147573A2 (fr) 2013-03-21 2014-03-19 Thérapie combinée

Publications (2)

Publication Number Publication Date
MA44934A1 MA44934A1 (fr) 2020-01-31
MA44934B1 true MA44934B1 (fr) 2021-11-30

Family

ID=50439443

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44934A MA44934B1 (fr) 2013-03-21 2014-03-19 Therapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur
MA38522A MA38522A1 (fr) 2013-03-21 2014-03-19 Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA38522A MA38522A1 (fr) 2013-03-21 2014-03-19 Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.

Country Status (33)

Country Link
US (3) US9913844B2 (fr)
EP (1) EP2976106B1 (fr)
JP (2) JP6449234B2 (fr)
KR (2) KR102446839B1 (fr)
CN (2) CN112641787A (fr)
AR (1) AR095699A1 (fr)
AU (1) AU2014233805B2 (fr)
BR (1) BR112015023483B8 (fr)
CA (1) CA2907704C (fr)
CL (2) CL2015002807A1 (fr)
CY (1) CY1124776T1 (fr)
DK (1) DK2976106T3 (fr)
EA (1) EA201591842A1 (fr)
ES (1) ES2870716T3 (fr)
GT (1) GT201500249A (fr)
HU (1) HUE055072T2 (fr)
IL (2) IL241188B (fr)
JO (1) JOP20140128B1 (fr)
MA (2) MA44934B1 (fr)
MX (1) MX374246B (fr)
MY (1) MY181085A (fr)
NZ (1) NZ712184A (fr)
PE (1) PE20151785A1 (fr)
PH (1) PH12015502040A1 (fr)
PL (1) PL2976106T3 (fr)
PT (1) PT2976106T (fr)
SG (2) SG10201906270VA (fr)
SI (1) SI2976106T1 (fr)
TN (1) TN2015000389A1 (fr)
TW (1) TWI603734B (fr)
UA (1) UA118846C2 (fr)
WO (1) WO2014147573A2 (fr)
ZA (1) ZA201800424B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
EP3154588A1 (fr) * 2014-06-13 2017-04-19 Genentech, Inc. Méthodes de traitement et de prévention de la résistance médicamenteuse du cancer
CN105753869B (zh) * 2015-04-01 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
PT3284481T (pt) * 2015-04-16 2024-06-04 Nitto Denko Corp Agente indutor da morte celular para células com mutação do gene braf, agente para inibição da proliferação das referidas células e composição farmacêutica para tratamento de pacientes que sofrem os efeitos da proliferação anormal das referidas células
BR112017021283A2 (en) * 2015-04-16 2018-06-26 Novartis Ag ribocyclib tablet
CN113893253A (zh) * 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
CN105732642B (zh) * 2015-11-18 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
KR20180115297A (ko) * 2016-02-19 2018-10-22 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브)
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
CN107058565A (zh) * 2016-08-31 2017-08-18 郭军 肢端型黑色素瘤的诊断和治疗
EP3515446B1 (fr) 2016-09-19 2023-12-20 Novartis AG Combinaisons thérapeutiques comprenant un inhibiteur de raf et un inhibiteur d'erk
KR20190103156A (ko) 2016-12-20 2019-09-04 에테하 취리히 암에서 비-유전적 약물 내성 프로그램을 표적으로 하는 약물의 동정
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
WO2018218633A1 (fr) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Polythérapies pour le traitement de cancers
WO2019195959A1 (fr) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Polythérapie pour cancers à mutation de braf
JP7507145B2 (ja) 2018-08-13 2024-06-27 ベイジン パーカンズ オンコロジー カンパニー リミテッド 癌治療のためのバイオマーカー
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2023212071A1 (fr) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combinaison et utilisation associée
CA3257280A1 (fr) 2022-05-25 2023-11-30 Msd International Gmbh Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
JP2025519981A (ja) * 2022-06-08 2025-06-30 マップキュア，エルエルシー Ｂ－ｒａｆ阻害剤によるがんの治療方法
WO2025003956A1 (fr) 2023-06-30 2025-01-02 Pfizer Inc. Formulations d'encorafénib à forte charge médicamenteuse

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003077855A2 (fr) 2002-03-13 2003-09-25 Array Biopharma, Inc Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060134068A1 (en) 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20090080530A (ko) * 2006-11-20 2009-07-24 노파르티스 아게 2-메틸-2-[4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조[4,5-ｃ]퀴놀린-1-일)-페닐]-프로피오니트릴의 염 및 결정 형태
MX393622B (es) * 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2010307043C1 (en) 2009-10-12 2014-03-13 Glaxosmithkline Llc Combination
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
WO2012068468A1 (fr) 2010-11-19 2012-05-24 Glaxosmithkline Llc Méthode de traitement utilisant un inhibiteur de la braf
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2012145503A1 (fr) * 2011-04-21 2012-10-26 Novartis Ag Combinaisons pharmaceutiques
WO2012178038A1 (fr) 2011-06-24 2012-12-27 The Broad Institute, Inc. Méthodes de traitement du cancer
EP2570127A1 (fr) 2011-09-16 2013-03-20 Sanofi Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
WO2013043715A1 (fr) * 2011-09-19 2013-03-28 Genentech, Inc. Polythérapies comportant des antagonistes de c-met et de b-raf
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP6342396B2 (ja) 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
DK2976106T3 (da) 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer

Also Published As

Publication number Publication date
MX2015013466A (es) 2016-06-21
IL241188A0 (en) 2015-11-30
GT201500249A (es) 2017-09-01
US9913844B2 (en) 2018-03-13
CA2907704A1 (fr) 2014-09-25
AU2014233805B2 (en) 2018-10-18
KR102446839B1 (ko) 2022-09-23
UA118846C2 (uk) 2019-03-25
TWI603734B (zh) 2017-11-01
PE20151785A1 (es) 2015-12-20
IL272921B (en) 2022-10-01
ZA201800424B (en) 2022-10-26
MA38522A1 (fr) 2017-10-31
NZ751830A (en) 2020-09-25
EA201591842A1 (ru) 2016-01-29
PH12015502040B1 (en) 2016-01-18
CN105209073A (zh) 2015-12-30
JP2016522160A (ja) 2016-07-28
IL272921B2 (en) 2023-02-01
WO2014147573A2 (fr) 2014-09-25
JP6742391B2 (ja) 2020-08-19
CY1124776T1 (el) 2022-11-25
CA2907704C (fr) 2023-01-10
CN112641787A (zh) 2021-04-13
US10548894B2 (en) 2020-02-04
JP2019055978A (ja) 2019-04-11
SI2976106T1 (sl) 2021-08-31
DK2976106T3 (da) 2021-06-14
HK1214135A1 (en) 2016-07-22
BR112015023483B1 (pt) 2022-07-19
AU2014233805A1 (en) 2015-10-01
SG10201906270VA (en) 2019-08-27
IL241188B (en) 2021-02-28
WO2014147573A3 (fr) 2014-12-11
US20160296520A1 (en) 2016-10-13
KR20150132205A (ko) 2015-11-25
BR112015023483A2 (pt) 2017-07-18
MY181085A (en) 2020-12-17
ES2870716T3 (es) 2021-10-27
JOP20140128B1 (ar) 2021-08-17
CL2018001371A1 (es) 2018-09-07
BR112015023483A8 (pt) 2019-12-03
CL2015002807A1 (es) 2016-05-13
PT2976106T (pt) 2021-05-26
IL272921A (en) 2020-04-30
JP6449234B2 (ja) 2019-01-09
SG11201507730UA (en) 2015-10-29
US20180221370A1 (en) 2018-08-09
HUE055072T2 (hu) 2021-10-28
MX374246B (es) 2025-03-05
PL2976106T3 (pl) 2021-10-25
NZ712184A (en) 2020-01-31
BR112015023483B8 (pt) 2023-01-31
TN2015000389A1 (en) 2017-01-03
AR095699A1 (es) 2015-11-04
US20200246338A1 (en) 2020-08-06
TW201440770A (zh) 2014-11-01
MA44934A1 (fr) 2020-01-31
KR102258698B1 (ko) 2021-06-01
PH12015502040A1 (en) 2016-01-18
KR20210110794A (ko) 2021-09-09
EP2976106B1 (fr) 2021-04-14
EP2976106A2 (fr) 2016-01-27

Similar Documents

Publication Publication Date Title
MA38522A1 (fr) Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
Govindan et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non–small-cell lung cancer
Ramalingam et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Sequist et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
Escudier et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
Girotti et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma
Cortés et al. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Gild et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
JP2014533272A5 (fr)
Pirazzoli et al. Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinoma
EP3147285A3 (fr) Composés de purinone en tant qu'inhibiteurs de kinase
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
Wells Jr et al. Update: the status of clinical trials with kinase inhibitors in thyroid cancer
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
Clement et al. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
RU2014117707A (ru) Способ лечения пролиферативного заболевания
Nabian et al. State of the neoadjuvant therapy for glioblastoma multiforme—Where do we stand?
Von Pawel et al. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects
RU2013126036A (ru) Способ лечения опухолей
Wu et al. A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
Geisler et al. Imiquimod in vulvar Paget's disease: a case report
Reck et al. JAVELIN lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC)
Xu et al. 1391TiP TACTC-2 trial: Efficacy of pembrolizumab±chemotherapy first-line therapy in advanced non-small cell lung cancer patients with PD-L1 expression≥ 50% adjusting in accordance with CtDNA
Podar Targeting mtDAMPed macrophages for MM therapy